Grimes & Company’s Array Biopharma Inc ARRY Stock Holding History

Grimes & Company’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-14,000	Closed	-$649K	–	263
2019 Q2	$649K	Hold	14,000	–	–	0.05%	154
2019 Q1	$341K	Hold	14,000	–	–	0.03%	189
2018 Q4	$200K	Hold	14,000	–	–	0.02%	222
2018 Q3	$213K	Hold	14,000	–	–	0.02%	224
2018 Q2	$235K	Hold	14,000	–	–	0.02%	211
2018 Q1	$228K	Buy	+14,000	New	+$224K	0.02%	209

Other funds holding ARRY

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Grimes & Company's ARRY Position: Q3 2019 in Review

Grimes & Company sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 14,000 shares — an estimated $649K sold.

Grimes & Company first reported a position in ARRY in Q1 2018 and held it in 6 quarters. The position peaked at $649K in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

Grimes & Company reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
Grimes & Company sold 14,000 Array Biopharma Inc shares in Q3 2019, an estimated $649K.
Grimes & Company first reported a position in Array Biopharma Inc in Q1 2018 and held it in 6 quarters.
Grimes & Company's Array Biopharma Inc position peaked at $649K in Q2 2019.
1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Grimes & Company's 13F filing for Q3 2019, filed 5 Nov 2019.